Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bellerophon Therapeutics, Inc. (BLPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.8400-0.1200 (-3.03%)
At close: 4:00PM EDT
4.0400 +0.20 (+5.21%)
After hours: 07:48PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.9600
Open3.8000
Bid3.8100 x 1000
Ask3.8800 x 900
Day's Range3.8000 - 3.9200
52 Week Range3.6600 - 9.7500
Volume45,382
Avg. Volume40,045
Market Cap36.505M
Beta (5Y Monthly)-0.58
PE Ratio (TTM)N/A
EPS (TTM)-2.7990
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • GlobeNewswire

    Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021. The presentation will be available on-demand beginning at 7:00 AM East

  • Simply Wall St.

    Here's Why We're Watching Bellerophon Therapeutics' (NASDAQ:BLPH) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • GlobeNewswire

    Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results

    WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021. “We continue to progress our INOpulse® inhaled nitric oxide therapy in multiple areas of significant unmet need,” said Fabian Tenenbaum, Chief Executive

Advertisement
Advertisement